Stay updated with breaking news from Randomized Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Emerald study met both its primary end points of Progression-free survival (PFS) in overall population and in ESR1 mutated patients PFS rate at 12 months with...
Data from four pivotal trials continue to build evidence base for BRUKINSA (zanubrutinib) in B-cell malignancies Pipeline showing promise with early data for BGB-11417, a BCL-2 inhibitor, as monotherapy
In a third interim analysis for the randomized Phase 2 ARC-7 study, both anti-TIGIT domvanalimab-containing arms continued to show meaningful differentiation compared to the anti-PD1 antibody zimberelimab alone when given as a treatment for first-line metastatic non-small cell lung cancer (NSCLC); we expect to provi...
10.05.2022 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that data for six approved medicines and pipeline candidates in more than 25 types of cancer will be presented at the 2022 American Society of Clinical Oncology ...
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business update for the quarter ended March 31, 2022. Over the first quarter of 2022, all of Transgene’s preclinical and clinical assets progressed in line with ...